Skip to main content
TCT 2026

CHAMPION-AF Substudy Finds Lower Proportion of Disabling Strokes After Left Atrial Appendage Closure

Disabling strokes occurred at a lower proportion in patients who underwent left atrial appendage closure (LAAC) than in those without an implanted device, according to the CHAMPION-AF stroke substudy presented at TCT 2026. However, the retrospective analysis was not powered to establish between-group differences in stroke characteristics or etiology.

Lauren S. Ranard, MD, MS, of Columbia University Irving Medical Center/NewYork-Presbyterian, presented the analysis of Clinical Events Committee-adjudicated strokes in patients with and without an implanted LAAC device; the parent trial, CHAMPION-AF, compared LAAC using WATCHMAN FLX with NOAC therapy. In this substudy, investigators examined patient demographics and LAA imaging, stroke timing, concurrent antithrombotic therapy, potential causes, and functional outcomes.

The 3-year results of CHAMPION-AF found LAAC noninferior to NOAC for the composite of cardiovascular death, stroke, or systemic embolism, and superior for the primary safety endpoint of nonprocedural bleeding. For all stroke, LAAC was associated with a rate of 3.6% vs NOAC’s 2.5%, with a hazard ratio of 1.46 (95% CI, 0.94-2.27).

Across the 3000-patient population in the parent study, 83 patients experienced stroke. Compared with patients without stroke, they were older, had higher CHA₂DS₂-VASc and HAS-BLED scores, and more frequently had prior stroke, transient ischemic attack, or thromboembolism.

Preimplant appendage anatomy did not differ significantly between LAAC patients with and without subsequent stroke. Likewise, 4-month imaging showed no significant differences in device-related thrombus or peridevice leak (PDL) between these groups, although PDL of at least 3 mm was more frequent in patients with stroke.

Among evaluable ischemic stroke events, the reported proportion classified as disabling at 90 days—modified Rankin Scale scores of 3-6—was 28.6% in implanted patients vs 48.1% in nonimplanted patients.

Stroke timing also differed. In implanted patients, 48.1% of observed events occurred within the first year, compared with 18.8% in nonimplanted patients. In the latter group, half of observed strokes occurred between 1 and 2 years (50.0%), with timing measured from implantation for implanted/crossover patients and from randomization for nonimplanted patients. At the time of stroke, 76.5% of implanted patients were receiving single antiplatelet therapy, while 75.0% of nonimplanted patients were receiving oral anticoagulation.

Interpretation of the findings should take the limitations of the study into consideration, which include the retrospective design, reliance on available records, availability of preimplant cardiac imaging only for the implant group, and limited event-related cardiac imaging. It is also important to note that atrial fibrillation was not the only possible contributor to stroke, as other risk factors were present in both groups.

 


Lauren S. Ranard, MD, MS, is an attending physician at the Columbia Structural Heart and Valve Center and Columbia Interventional Cardiovascular Care at Columbia University Irving Medical Center/NewYork-Presbyterian Hospital, and a full-time faculty member and Assistant Professor of Medicine at Columbia University Irving Medical Center.

© 2026 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of the Journal of Invasive Cardiology or HMP Global, their employees, and affiliates.